Marbofloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Marbofloxacin
Accession Number
DB11426
Type
Small Molecule
Groups
Vet approved
Description

Marbofloxacin is a carboxylic acid, part of the third generation of antibiotic fluoroquinolones. It is used in veterinary. A formulation of marbofloxacin combined with clotrimazole and dexamethasone is available under the name Aurizon.

Structure
Thumb
Synonyms
  • Marbofloxacin
External IDs
RO 09-1168
Categories
UNII
8X09WU898T
CAS number
115550-35-1
Weight
Average: 362.361
Monoisotopic: 362.139033271
Chemical Formula
C17H19FN4O4
InChI Key
BPFYOAJNDMUVBL-UHFFFAOYSA-N
InChI
InChI=1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)
IUPAC Name
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN3N(C)COC1=C23)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Marbofloxacin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Marbofloxacin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Marbofloxacin is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Marbofloxacin is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Marbofloxacin.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Marbofloxacin.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Marbofloxacin.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Marbofloxacin.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Marbofloxacin.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Marbofloxacin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Shen J, Qian JJ, Gu JM, Hu XR: Marbofloxacin. Acta Crystallogr Sect E Struct Rep Online. 2012 Apr 1;68(Pt 4):o998-9. doi: 10.1107/S1600536812009312. Epub 2012 Mar 10. [PubMed:22590047]
  2. Bousquet-Melou A, Bernard S, Schneider M, Toutain PL: Pharmacokinetics of marbofloxacin in horses. Equine Vet J. 2002 Jul;34(4):366-72. [PubMed:12117108]
  3. Illambas J, Potter T, Cheng Z, Rycroft A, Fishwick J, Lees P: Pharmacodynamics of marbofloxacin for calf pneumonia pathogens. Res Vet Sci. 2013 Jun;94(3):675-81. doi: 10.1016/j.rvsc.2012.12.012. Epub 2013 Jan 31. [PubMed:23375665]
  4. Anadon A, Martinez-Larranaga MR, Diaz MJ, Martinez MA, Frejo MT, Martinez M, Tafur M, Castellano VJ: Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens. Am J Vet Res. 2002 Jul;63(7):927-33. [PubMed:12118670]
  5. Peyrou M, Doucet MY, Vrins A, Concordet D, Schneider M, Bousquet-Melou A: Population pharmacokinetics of marbofloxacin in horses: preliminary analysis. J Vet Pharmacol Ther. 2004 Oct;27(5):283-8. [PubMed:15500564]
  6. Lefebvre HP, Dupouy V, Schneider M, Laroute V, Toutain PL: Pharmacokinetics of marbofloxacin in renal impairment in the dog. Vet Q. 1998;20 Suppl 1:S104. [PubMed:9652038]
  7. Haritova AM, Rusenova NV, Parvanov PR, Lashev LD, Fink-Gremmels J: Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys. Antimicrob Agents Chemother. 2006 Nov;50(11):3779-85. Epub 2006 Aug 28. [PubMed:16940071]
  8. Carpenter JW, Hunter RP, Olsen JH, Henry H, Isaza R, Koch DE: Pharmacokinetics of marbofloxacin in blue and gold macaws (Ara ararauna). Am J Vet Res. 2006 Jun;67(6):947-50. [PubMed:16740085]
  9. Schneider M, Thomas V, Boisrame B, Deleforge J: Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J Vet Pharmacol Ther. 1996 Feb;19(1):56-61. [PubMed:8992027]
External Links
KEGG Drug
D08156
ChemSpider
54663
ChEBI
94723
ChEMBL
CHEMBL478120
Wikipedia
Marbofloxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.6 mg/mLALOGPS
logP-0.53ALOGPS
logP-0.045ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)5.38ChemAxon
pKa (Strongest Basic)6.16ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area76.56 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity103.02 m3·mol-1ChemAxon
Polarizability35.92 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0229-3049000000-014725600c65e721b0c4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0009000000-3cc733f0d48f0efab4a0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9004000000-7a6c1591747b31e05842
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9010000000-88c53df7784f418e4946
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9110000000-1928ad3796067a4d5980
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9410000000-7d5850dc02949a2ec321
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9800000000-53b4c277a884f24dce27
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-7900000000-ce3aee917b31d0ea3a12
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05di-9500000000-a4720551cd6269bf3188
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-056r-9200000000-6c8fabe0456090287dfa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0129000000-2a6e9ed702ca173c3dfb

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Aminoquinolines and derivatives / Haloquinolines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines / Benzenoids
show 14 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Tertiary aliphatic/aromatic amine
show 31 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on February 25, 2016 11:40 / Updated on June 04, 2019 07:21